New data put Lundbeck firmly on GSK's tail in 5HT6 inhibitor Alzheimer's race
This article was originally published in Scrip
Lundbeck's novel selective 5HT6 receptor inhibitor Lu AE58054 may have fallen at the Phase II hurdle in schizophrenia, but the company seems to be reaping the rewards of pursuing its development in the notoriously difficult indication of Alzheimer's disease.
You may also be interested in...
The US FDA has given the go-ahead for marketing of ViiV healthcare’s novel HIV drug just as the EMA removes the accelerated assessment status from its application there.
Executives On The Move: BioXcel Therapeutics Picks A Development Officer, A Finance Hire At RenovaCare And CANbridge Taps Takeda Talent
Immuno-oncology and neuroscience firm BioXcel Therapeutics picks a chief development officer, and stem-cell therapy company RenovaCare hires a CFO. Plus, CANbridge Life Sciences, developer of specialty health products, adds Takeda Pharma rare disease lead as global head, business development.
Topline Phase II data for the antibody-drug conjugate tisotumab vedotin put it on a swift path towards approval in cervical cancer.